Theriva Biologics Balance Sheet Health
Financial Health criteria checks 5/6
Theriva Biologics has a total shareholder equity of $27.6M and total debt of $155.0K, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are $42.4M and $14.7M respectively.
Key information
0.6%
Debt to equity ratio
US$155.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$16.59m |
| Equity | US$27.65m |
| Total liabilities | US$14.74m |
| Total assets | US$42.39m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SFY0's short term assets ($19.7M) exceed its short term liabilities ($6.8M).
Long Term Liabilities: SFY0's short term assets ($19.7M) exceed its long term liabilities ($7.9M).
Debt to Equity History and Analysis
Debt Level: SFY0 has more cash than its total debt.
Reducing Debt: SFY0's debt to equity ratio has increased from 0% to 0.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SFY0 has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: SFY0 is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.